Essential thrombocytosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Essential thrombocytosis

Essential thrombocytosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Essential thrombocytosis (primary thrombocythemia) is a nonreactive, chronic myeloproliferative disorder in which sustained megakaryocyte proliferation leads to an increase in the number of circulating platelets. Mutations in JAK2, CALR, or MPL are found in approximately 90% of patients with essential thrombocytosis.

Essential thrombocytosis is characterized by the following:
Platelet count > 450,000/µL
Megakaryocytic hyperplasia
Splenomegaly
A clinical course complicated by thrombotic or hemorrhagic episodes or both.

Epidemiology-
According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the incidence of Essential thrombocytosis is between a range of 0.42 to 1.68 per 100,000 in the EU countries, whereas incidence is reported much higher between a range of 2.25 to 2.37 per 100,000 in the United States.

Competitive landscape of Essential thrombocytosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Essential thrombocytosis 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Essential thrombocytosis market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Essential thrombocytosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 Ropeginterferon alfa-2b PharmaEssentia Phase 3
2 Ropeginterferon alfa-2b Medpace, Inc. Phase 3
3 IMG-7289 Imago BioSciences,Inc. Phase 2
4 Pacritinib PSI CRO Phase 3
5 Anagrelide retard AOP Orphan Pharmaceuticals AG Phase 3
6 anagrelide hydrochloride Takeda Phase 2
7 SPD422 (anagrelide hydrochloride) Shire Phase 3
8 Imetelstat Geron Corporation Phase 2
9 LY573636-sodium Eli Lilly and Company Phase 1
10 NS-018 NS Pharma, Inc. Phase 2
11 Pacritinib CTI BioPharma Phase 2
12 PXS-5505 Pharmaxis Phase 2
13 itacitinib Incyte Corporation Phase 2
14 PU-H71 Samus Therapeutics, Inc. Phase 1
15 KRT-232 Kartos Therapeutics, Inc. Phase 3
16 RG7388 Roche Pharma AG Phase 1
17 AZD1480 AstraZeneca Phase 1
18 INC424 Novartis Pharmaceuticals Phase 3
19 MMB Sierra Oncology, Inc. Phase 2
20 SAR302503 Sanofi Phase 2
21 Simtuzumab Gilead Sciences Phase 2
22 PEGASYS Ronald Hoffman Phase 3
23 Anagrelide CR Galena Biopharma, Inc. Phase 2
24 Selinexor Karyopharm Therapeutics Inc Phase 2
25 APLIDIN (plitidepsin) PharmaMar Phase 2
26 LNK01002 Lynk Pharmaceuticals Co., Ltd Phase 1
27 LY2784544 Eli Lilly and Company Phase 1
28 CPI-0610 Constellation Pharmaceuticals Phase 3
29 givinostat Italfarmaco Phase 2
30 rigosertib Onconova Therapeutics, Inc. Phase 2
31 Luspatercept Celgene Phase 2
32 Ruxolitinib Actuate Therapeutics Inc. Phase 2
33 Navitoclax AbbVie Phase 1
34 TAS1553 Astex Pharmaceuticals, Inc. Phase 1
35 Ruxolitinib Helsinn Healthcare SA Phase 2
36 busulfan Otsuka America Pharmaceutical Phase 2